NATICK, Mass. - Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that data and acute results from its CorPath PRECISE Trial will be presented during a ...

Study launched to evaluate the effectiveness of CorPath robotic assistance in performing balloon angioplasty for symptomatic peripheral arterial disease WALTHAM, MA, February 24, 2015 – Corindus ...

The FDA has granted clearance for the CorPath 200 System, a robotic system that assists heart surgeons in restoring blood flow to blocked coronary arteries. Corindus Vascular Robotics, a Natick, MA ...

WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that the U.S. Food and Drug Administration has ...

The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation ...

Renowned medical journal publishes the successful clinical results of remote PCI procedures using CorPath® GRX Robotic System technology To improve patient outcomes and broaden access to high-level ...

There are also other challenges within the procedure including issues of precision and proper stent selection, a phenomenon known as longitudinal geographic miss (LGM), which is caused by sub-optimal ...

Breakfast symposium and conference activities to highlight capabilities of vascular robotic technology and advancements in automation and remote treatment • “Clinical Review” presented by Ehtisham ...

The first-in-human clinical study of the CorPath 200 System performed at the Corbic Research Institute, Envigado, Colombia, was conducted on eight patients to evaluate the safety and technical ...

Data demonstrates safety and efficacy of robotic-assisted percutaneous coronary interventions, while enhancing control and radiation protection for interventional cardiologists “This study has the ...